Literature DB >> 8613937

Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.

M Bourrié1, V Meunier, Y Berger, G Fabre.   

Abstract

Cytochrome P450 chemical inhibitors are widely used to define the role of individual cytochrome P450 isozyme(s) in a metabolism process. In this study, cytochrome P450 isoform-dependent reactions were investigated on our human liver microsomes bank (n = 34) and characterized for both KM and VMAX values (n > or = 3). These metabolic reactions were: 7-ethoxyresorufin O-deethylation (CYP1A1), phenacetin O-deethylation (CYP1A2), coumarin 7-hydroxylation (CYP2A6), tolbutamide 4-methylhydroxylation (CYP2C9), dextromethorphan O-demethylation (CYP2D6), aniline 4-hydroxylation (CYP2E1) and nifedipine dehydrogenation (CYP3A4). Literature data-based specific inhibitors were selected and characterized for both their inhibitory constant (Ki) and the inhibition-type toward their specific substrate. Results were as follows: alpha-naphthoflavone (CYP1A1; mixed-type interaction with a Ki = 0.01 microM), furafylline (CYP1A2; competitive-type interaction with a Ki = 3 microM when microsomes were incubated with both furafylline and phenacetin; noncompetitive-type interaction with a Ki = 0.6 microM when microsomes were preincubated with furafylline and NADPH), pilocarpine (CYP2A6; competitive-type interaction with a Ki = 4 microM), sulfaphenazole (CYP2C9; competitive-type interaction with a Ki = 0.3 microM), quinidine (CYP2D6; competitive-type interaction with a Ki = 0.4 microM, diallyldisulfide (CYP2E1; noncompetitive-type interaction with a Ki = 150 microM on an aniline concentration range of 10-60 microM; competitive-type interaction with a Ki = 100 microM on an aniline concentration range of 80-2000 microM) and ketoconazole (CYP3A4; mixed-type interaction with a Ki = 0.015 microM). Once the inhibitors' potency was determined, the selective effects of these inhibitors were evaluated after incubation of human hepatic microsomes with isoform-selective substrates in the presence of the different chemical inhibitors. Up to 10 times the Ki value toward the isoform-selective probe, pilocarpine, sulfaphenazole, quinidine and ketoconazole exhibited potent inhibitory and specific effects. alpha-Naphthoflavone and furafylline both inhibited phenacetin and 7-ethoxyresorufin O-deethylation processes, a consequence of the absence of CYP1A1 in noninduced human liver. Diallyldisulfide exhibited broad and nonspecific inhibitory effects. When used in their "window of selectivity," ie., up to 10-fold the Ki value, most chemical inhibitors powerfully and specifically inhibited cytochrome P450 isoform-specific reactions when analyzed at their KM values.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8613937

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  45 in total

1.  CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.

Authors:  K E Kenworthy; J C Bloomer; S E Clarke; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

2.  Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine.

Authors:  O V Olesen; K Linnet
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

3.  Comparison of in vitro hepatic models for the prediction of metabolic interaction between simvastatin and naringenin.

Authors:  N Le Goff; J C Koffel; S Vandenschrieck; L Jung; G Ubeaud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Oct-Dec       Impact factor: 2.441

4.  Rapidly distinguishing reversible and irreversible CYP450 inhibitors by using fluorometric kinetic analyses.

Authors:  Z Yan; B Rafferty; G W Caldwell; J A Masucci
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Oct-Dec       Impact factor: 2.441

5.  Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells.

Authors:  Amandeep Mann; Rachel F Tyndale
Journal:  Eur J Neurosci       Date:  2010-03-22       Impact factor: 3.386

Review 6.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

7.  Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation.

Authors:  Evan T Ogburn; David R Jones; Andrea R Masters; Cong Xu; Yingying Guo; Zeruesenay Desta
Journal:  Drug Metab Dispos       Date:  2010-03-24       Impact factor: 3.922

8.  In vitro cytochrome P450-mediated metabolism of exemestane.

Authors:  Landry K Kamdem; David A Flockhart; Zeruesenay Desta
Journal:  Drug Metab Dispos       Date:  2010-09-28       Impact factor: 3.922

9.  Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers.

Authors:  Annika Allqvist; Jun Miura; Leif Bertilsson; Rajaa A Mirghani
Journal:  Eur J Clin Pharmacol       Date:  2007-01-03       Impact factor: 2.953

10.  A Bayesian meta-analysis on published sample mean and variance pharmacokinetic data with application to drug-drug interaction prediction.

Authors:  Menggang Yu; Seongho Kim; Zhiping Wang; Stephen Hall; Lang Li
Journal:  J Biopharm Stat       Date:  2008       Impact factor: 1.051

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.